Possible antiviral effect of ciprofloxacin treatment on polyomavirus BK replication and analysis of non-coding control region sequences

Virology Journal

Anna Paola Mitterhofer¹  Valeria Pietropaolo³  Carlo Mancini²  Donatella Maria Rodio²  Anna Bellizzi²  Assunta Zavatto¹  Francesca Tinti¹  Elena Anzivino²  Ilaria Umbro¹ 

[1] Department of Clinical Medicine, Nephrology and Dialysis Unit, “Sapienza” University of Rome, Viale dell’Università 37, Rome 00185, Italy;Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, Rome Italy;Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania, USA

关键词: Viral protein 1;    Non-coding control region;    Acute renal dysfunction;    Renal transplant;    Ciprofloxacin;    Fluoroquinolones;    Polyomavirus BK infection;   

Others  :  821755
DOI  :  10.1186/1743-422X-10-274

 received in 2013-04-29, accepted in 2013-08-26,  发布年份 2013

【 摘 要 】

Acute renal dysfunction (ARD) is a common complication in renal transplant recipients. Multiple factors contribute to ARD development, including acute rejection and microbial infections. Many viral infections after kidney transplantation result from reactivation of “latent” viruses in the host or from the graft, such as the human Polyomavirus BK (BKV). We report the case of a 39 year-old recipient of a 2^nd kidney graft who experienced BKV reactivation after a second episode of acute humoral rejection. A 10-day treatment with the quinolone antibiotic ciprofloxacin was administered with an increase of immunosuppressive therapy despite the active BKV replication. Real Time PCR analysis performed after treatment with ciprofloxacin, unexpectedly showed clearance of BK viremia and regression of BK viruria. During the follow-up, BK viremia persisted undetectable while viruria decreased further and disappeared after 3 months.

BKV non-coding control region sequence analysis from all positive samples always showed the presence of archetypal sequences, with two single-nucleotide substitutions and one nucleotide deletion that, interestingly, were all representative of the subtype/subgroup I/b-1 we identified by the viral protein 1 sequencing analysis.

We report the potential effect of the quinolone antibiotic ciprofloxacin in the decrease of the BKV load in both blood and urine.

【 授权许可】

   
2013 Umbro et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Moreso F, Hernández D: Has the survival of the graft improved after renal transplantation in the era of modern immunosuppression? Nefrologia 2013, 33(1):14-26.
• [2]Cukuranovic J, Ugrenovic S, Jovanovic I, Visnjic M, Stefanovic V: Viral infection in renal transplant recipients. Sci World J 2012, 2012:820621.
• [3]Wu C, Randhawa P, McCauley J: Transplantation: polyomavirus nephropathy and the risk of specific immunosuppression regimens. Sci World J 2006, 28:512-528.
• [4]Wiseman AC: Polyomavirus nephropathy: a current perspective and clinical considerations. Am J Kidney Dis 2009, 54:131-142.
• [5]Kuypers DR: Management of polyomavirus-associated nephropathy in renal transplant recipients. Nat Rev Nephrol 2012, 8(7):390-402.
• [6]Dharnidharka VR, Cherikh WS, Abbott KC: An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation 2009, 87:1019-1026.
• [7]Prince O, Savic S, Dickenmann M, Steiger J, Bubendorf L, Mihatsch MJ: Risk factors for polyoma virus nephropathy. Nephrol Dial Transplant 2009, 24(3):1024-1033.
• [8]Schold JD, Rehman S, Kayle LK, Magliocca J, Srinivas TR, Meier-Kriesche HU: Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transpl Int 2009, 22(6):626-634.
• [9]Hirsch HH, Brennan DC, Drachenberg CB, Ginevri F, Gordon J, Limaye AP, Mihatsch MJ, Nickeleit V, Ramos E, Randhawa P, Shapiro R, Steiger J, Suthanthiran M, Trofe J: Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005, 79(10):1277-1286.
• [10]Brennan DC, Agha I, Bohl DL, Schnitzler MA, Hardinger KL, Lockwood M, Torrence S, Schuessler R, Roby T, Gaudreault-Keener M, Storch GA: Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005, 5(3):582-594.
• [11]Saad ER, Bresnahan BA, Cohen EP, Lu N, Orentas RJ, Vasudev B, Hariharan S: Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. Transplantation 2008, 85(6):850-854.
• [12]Bonvoisin C, Weekers L, Xhignesse P, Grosch S, Milicevic M, Krzesinski JM: Polyomavirus in renal transplantation: a hot problem. Transplantation 2008, 85(Suppl 7):42-48.
• [13]Ramos E, Drachenberg CB, Wali R, Hirsch HH: The decade of polyomavirus BK-associated nephropathy: state of affairs. Transplantation 2009, 87(5):621-630.
• [14]Hirsch HH, Knowles W, Dickenmann M, Passweg J, Klimkait T, Mihatsch MJ, Steiger J: Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002, 347(7):488-496.
• [15]Wojciechowski D, Chanda R, Chandran S, Lee B, Webber A, Macaraig M, Tomlanovich S, Vincenti F: Ciprofloxacin prophylaxis in kidney transplant recipients reduces BK virus infection at 3 months but not at 1 year. Transplantation 2012, 94(11):1117-1123.
• [16]Trofe J, Hirsch HH, Ramos E: Polyomavirus-associated nephropathy: update of clinical management in kidney transplant patients. Transpl Infect Dis 2006, 8(2):76-85.
• [17]Roskopf J, Trofe J, Stratta RJ, Ahsan N: Pharmacotherapeutic options for the management of human polyomaviruses. Adv Exp Med Biol 2006, 577:228-254.
• [18]Rinaldo CH, Hirsch HH: Antivirals for the treatment of polyomavirus BK replication. Expert Rev Anti Infect Ther 2007, 5(1):105-115.
• [19]Sharma BN, Li R, Bernhoff E, Gutteberg TJ, Rinaldo CH: Fluoroquinolones inhibit human polyomavirus BK (BKV) replication in primary human kidney cells. Antiviral Res 2011, 92(Suppl 1):115-123.
• [20]Ali SH, Chandraker A, DeCaprio JA: Inhibition of Simian virus 40 large T antigen helicase activity by fluoroquinolones. Antivir Ther 2007, 12(Suppl 1):1-6.
• [21]Portolani M, Pietrosemoli P, Cermelli C, Mannini-Palenzona A, Grossi MP, Paolini L, Barbanti-Brodano G: Suppression of BK virus replication and cytopathic effect by inhibitors of prokaryotic DNA gyrase. Antiviral Res 1988, 9(3):205-218.
• [22]Leung AY, Chan MT, Yuen KY, Cheng VC, Chan KH, Wong CL, Liang R, Lie AK, Kwong YL: Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2005, 40(4):528-537.
• [23]Randhawa PS: Anti-BK virus activity of ciprofloxacin and related antibiotics. Clin Infect Dis 2005, 41(9):1366-1367.
• [24]Gabardi S, Waikar SS, Martin S, Roberts K, Chen J, Borgi L, Sheashaa H, Dyer C, Malek SK, Tullius SG, Vadivel N, Grafals M, Abdi R, Najafian N, Milford E, Chandraker A: Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. Clin J Am Soc Nephrol 2010, 5(7):1298-1304.
• [25]Cekmen MB, Bakirdoven S, Sayan M, Yilmaz A: BK virus nephropathy developing after renal transplantation and its treatment with ciprofloxacin: a case report. Transplant Proc 2012, 44(Suppl 10):3044-3047.
• [26]Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, Campbell PM, Cascalho M, Collins AB, Demetris AJ, Drachenberg CB, Gibson IW, Grimm PC, Haas M, Lerut E, Liapis H, Mannon RB, Marcus PB, Mengel M, Mihatsch MJ, Nankivell BJ, Nickeleit V, Papadimitriou JC, Platt JL, Randhawa P, Roberts I, Salinas-Madriga L, Salomon DR, Seron D, Sheaff M, et al.: Banff 05 meeting report : differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (‘CAN’). Am J Transplant 2007, 7:518-526.
• [27]Drachenberg CB, Hirsch HH, Ramos E, Papadimitriou JC: Polyomavirus disease in renal transplantation: review of pathological findings and diagnostic methods. Hum Pathol 2005, 36(Suppl 12):1245-1255.
• [28]Randhawa P, Brennan DC: BK virus infection in transplant recipients: an overview and update. Am J Transplant 2006, 6:2000-2005.
• [29]Vats A, Randhawa PS, Shapiro R: Diagnosis and treatment of BK virus-associated transplant nephropathy. Adv Exp Med Biol 2006, 577:213-227.
• [30]Miller AN, Glode A, Hogan KR, Schaub C, Kramer C, Stuart RK, Costa LJ: Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2011, 17(Suppl 8):1176-1181.
• [31]Anzivino E, Bellizzi A, Mitterhofer AP, Tinti F, Barile M, Colosimo MT, Fioriti D, Mischitelli M, Chiarini F, Ferretti G, Taliani G, Pietropaolo V: Early monitoring of the human polyomavirus BK replication and sequencing analysis in a cohort of adult kidney transplant patients treated with basiliximab. Virol J 2011, 8:407. BioMed Central Full Text
• [32]Yogo Y, Zhong S, Xu Y, Zhu M, Chao Y, Sugimoto C, Ikegaya H, Shibuya A, Kitamura T: Conserved archetypal configuration of the transcriptional control region during the course of BK polyomavirus evolution. J Gen Virol 2008, 89(Suppl 8):1849-1856.
• [33]Zhong S, Randhawa PS, Ikegaya H, Chen Q, Zheng HY, Suzuki M, Takeuchi T, Shibuya A, Kitamura T, Yogo Y: Distribution patterns of BK polyomavirus (BKV) subtypes and subgroups in American, European and Asian populations suggest co-migration of BKV and the human race. J Gen Virol 2009, 90(Suppl 1):144-152.
• [34]Jin L, Gibson PE, Knowles WA, Clewley JP: BK virus antigenic variants: sequence analysis within the capsid VP1 epitope. J Med Virol 1993, 39(Suppl 1):50-56.
• [35]Moens U, Van-Ghelue M: Polymorphism in the genome of non-passaged human polyomavirus BK: implications for cell tropism and the pathological role of the virus. Virology 2005, 331(Suppl 2):209-231.
• [36]Olsen GH, Hirsch HH, Rinaldo CH: Functional analysis of polyomavirus BK non-coding control region quasispecies from kidney transplant recipients. J Med Virol 2009, 81(Suppl 11):1959-1967.
• [37]Yoshiike K, Takemoto KK: Studies with BK virus and monkey lymphotropic papovavirus. In The papovaviridae. Edited by Salzman NP. New York: Plenum Publishing Corp; 1986:295-326.
• [38]Cole C, Conzen S: Polyomaviridae: the viruses and their replication. In Fields virology. 4th edition. Edited by Knipe D, Howley P, Griffin D, Lamb R, Martin M, Roizman B, Straus S. Philadelphia: Lippincott Williams & Wilkins; 2001:2141-2174.